Vaccitech Aims to Revolutionize Disease Prevention with CHADOX Technology

Vaccitech, a Nasdaq-listed spinoff company founded by Oxford University scientists, is working on a new generation of vaccines using the CHADOX technology, which has shown promising results in fighting a range of diseases, including several cancers, hepatitis B, shingles, and Middle East Respiratory Syndrome (Mers). This technology, developed in partnership with AstraZeneca, uses a chimpanzee adenovirus vector to deliver the active ingredient of the vaccine into the body, stimulating a response from the immune system. Alongside Vaccitech, other scientists are using CHADOX to develop vaccines for at least 11 other diseases, from malaria to the plague.

Key Takeaways:

• Vaccitech is a Nasdaq-listed spinoff company founded by Oxford University scientists, aiming to develop vaccines using the CHADOX technology.
• CHADOX uses a chimpanzee adenovirus vector to deliver the active ingredient of the vaccine into the body, stimulating a response from the immune system.
• The technology has shown promising results in fighting a range of diseases, including several cancers, hepatitis B, shingles, and Middle East Respiratory Syndrome (Mers).
• Vaccitech is working on shots to treat diseases including several cancers and hepatitis B, as well as to prevent shingles and Middle East Respiratory Syndrome (Mers).
• Other scientists are using CHADOX to develop vaccines for at least 11 other diseases, from malaria to the plague.
• Promising early results have been posted for jabs using CHADOX to tackle chikungunya virus as well as Nipah virus, which has known pandemic potential.
• Scientists have believed for several decades that adenovirus vector platforms would work as a new route for delivering vaccines.

Statistics:

• 11 other diseases are being targeted by vaccines using CHADOX technology.
• Behind the mRNA vaccines, CHADOX is a "plug and play" platform, where the backbone of the vaccine remains the same, while the detail of the disease it is showing the immune system can be altered.

Sources:

• A COMPANY founded by the Oxford University scientists who spearheaded the Covid-19 vaccine
• Tom Evans, chief scientific officer at Vaccitech
• Scientists have believed for several decades that adenovirus vector platforms would work as a new route for delivering vaccines